Wednesday, July 8, 2026

biotech · Glioblastoma · Recurrent Brain Metastases · GTBP

GT Biopharma

GT Biopharma is a biotech organization headquartered in Brisbane, USA. It trades on NYSE under ticker GTBP. Primary therapeutic focus areas include Glioblastoma, Recurrent Brain Metastases, High-risk Myelodysplastic Synd

Brisbane, USA HQ
1973 Founded
8 Employees
Public company Type
GTBP · NYSE Ticker
Company details
Status
Public
HQ
Brisbane, USA
Founded
1973
Employees
8
Programs
8
Drugs
7
Patents
1
Clinical program

Semaglutide

Unknown · small molecule · Obesity (Disorder)

Semaglutide for Obesity (Disorder) is a Unknown program (small_molecule) at GT Biopharma with 1 ClinicalTrials.gov record(s).

← All GT Biopharma projects Unknown small molecule active

Internal code GTM-021

Full intelligence profile for this program is being prepared.

At a glance

Sponsor
GT Biopharma
Phase
Unknown
Modality
small_molecule
Indication
Obesity (Disorder)
Status
active
Trials
1